Gilead Sciences (GILD) call put ratio 2.3 calls to 1 put after FT says remdesivir failed in first trial
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $131.27 +4.21%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +4.4%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +4.4%
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) 30-day option implied volatility is at 52; compared to its 52-week range of 19 to 108 after FT says remdesivir failed in first trial. Call put ratio 2.3 calls to 1 put.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX (SPCX) call put ratio 2 calls to 1 put as share price at $160
- AMD (AMD) call put ratio 1.4 calls to 1 put as share price down 4.3%
- Alcoa (AA) call put ratio 1 call to 1 put on 29K contracts as share price down 10%
Create E-mail Alert Related Categories
OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
